Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Amneal Pharmaceuticals, Inc. reported full year ended December 31, 2023 results: revenue $2.39 billion, net income GAAP Net Loss of $84 million, EPS Diluted Loss per Share of $0.48. Guidance initiated.
- Period
- full year ended December 31, 2023
- Revenue
- $2.39 billion
- Net income
- GAAP Net Loss of $84 million
- EPS
- Diluted Loss per Share of $0.48
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Adjusted Net Income (1) of $198 million; Adjusted EBITDA (1) of $558 million; Adjusted Diluted
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Amneal Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $617 million, net income GAAP Net Loss of $99 million, EPS Diluted Loss per Share of $0.40. Guidance initiated.
- Period
- fourth quarter and full year ended December 31, 2023
- Revenue
- $617 million
- Net income
- GAAP Net Loss of $99 million
- EPS
- Diluted Loss per Share of $0.40
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
--- AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1)
View on SEC.gov